Ken Griffin Abb Vie Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,467,500 shares of ABBV stock, worth $414 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

2,467,500

Previous 2,617,800 5.74%

Holding current value

$414 Million

Previous $449 Million 8.52%

% of portfolio

0.1%

Previous 0.09%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $40.5 Million - $49.3 Million	247,195 New	247,195 $48.8 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $83.7 Million - $95.3 Million	-523,426 Reduced 98.87%	5,968 $1.09 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $357 Million - $402 Million	-2,596,834 Reduced 83.07%	529,394 $82 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $160 Million - $185 Million	1,195,188 Added 61.89%	3,126,228 $466 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $44.2 Million - $55 Million	-333,303 Reduced 14.72%	1,931,040 $260 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $258 Million - $297 Million	1,785,323 Added 372.7%	2,264,343 $361 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $6.04 Million - $7.24 Million	-43,650 Reduced 8.35%	479,020 $77.5 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $5.31 Million - $6.09 Million	-39,540 Reduced 7.03%	522,670 $70.1 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $56.8 Million - $72.2 Million	-412,681 Reduced 42.33%	562,210 $86.1 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $637,595 - $791,076	-4,831 Reduced 0.49%	974,891 $158 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $16 Million - $20.2 Million	-148,952 Reduced 13.2%	979,722 $133 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $102 Million - $116 Million	958,531 Added 563.37%	1,128,674 $122 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $101 Million - $113 Million	-964,097 Reduced 85.0%	170,143 $19.2 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $13.5 Million - $14.8 Million	-131,697 Reduced 10.4%	1,134,240 $123 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $63.3 Million - $85.4 Million	786,013 Added 163.78%	1,265,937 $136 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $254 Million - $298 Million	-2,952,488 Reduced 86.02%	479,924 $42 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $132 Million - $177 Million	-1,804,079 Reduced 34.45%	3,432,412 $337 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $160 Million - $243 Million	2,485,870 Added 90.37%	5,236,491 $399 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $172 Million - $215 Million	2,378,946 Added 640.06%	2,750,621 $244 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $131 Million - $158 Million	-2,081,158 Reduced 84.85%	371,675 $28.1 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $119 Million - $152 Million	1,810,774 Added 282.03%	2,452,833 $178 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $48 Million - $56.5 Million	622,319 Added 3152.58%	642,059 $0
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $118 Million - $146 Million	-1,519,899 Reduced 98.72%	19,740 $1.82 Million
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $16.6 Million - $18.5 Million	-187,012 Reduced 10.83%	1,539,639 $0
Q2 2018 Aug 10, 2018	BUY	$89.78 - $106.23 $121 Million - $143 Million	1,345,279 Added 352.75%	1,726,651 $0
Q1 2018 May 11, 2018	BUY	$92.01 - $123.21 $7.33 Million - $9.82 Million	79,718 Added 26.43%	381,372 $36.1 Million
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $12.2 Million - $13.3 Million	135,766 Added 81.84%	301,654 $29.2 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $11.6 Million - $14.8 Million	165,888	165,888 $14.7 Million

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $297B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account